CDC45

Across TCGA pan-cancer cohorts, CDC45 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CDC45 data layer compared with 30 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher CDC45 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CDC45 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

LUSC, STAD, and LIHC are the cancer types where CDC45 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.079	0.792	<.001	30	view →
STAD	OS	Median	All	0.184	0.730	.001	18	view →
LIHC	OS	Median	All	0.015	0.784	<.001	18	view →
UCEC	DFS	Median	II,III,IV	0.933	0.302	.007	14	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BLCA	DFS	Median	II,III,IV	0.885	0.607	.039	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CDC45–LUSC (DFS)

Open the LUSC breakdown →